E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 3/1/2019 in the Prospect News Convertibles Daily.

Danaher greenshoe ups 4.75% convertible preferreds to $1.65 billion

By Wendy Van Sickle

Columbus, Ohio, March 1 – Underwriters for Danaher Corp.’s 4.75% three-year series A mandatory convertible preferred stock fully exercised their $150 million greenshoe, lifting the total deal size to $1.65 billion, according to a news release on Friday.

The company priced $1.5 billion of the convertible preferreds at of par of $1,000 after the market close on Tuesday with an initial conversion premium of 22.5%, as previously reported.

Pricing came richer than initial price talk for a dividend of 5.25% to 5.75% and at the rich end of talk for an initial conversion premium of 17.5% to 22.5%, according to a market source.

Barclays, Goldman Sachs & Co. LLC, Credit Suisse Securities (USA) LLC and HSBC Securities (USA) Inc. are the bookrunners for the registered offering.

The initial size of the deal was $1.35 billion with a greenshoe of $135 million.

The mandatory convertible preferred stock priced concurrently with a $1.35 billion, or 11 million share, common stock offering, which priced at $123.00 per share.

The common share offering carried a greenshoe of $135 million, which was also exercised in full.

The mandatory convertible preferred stock has takeover and dividend protection for dividend payments above 22 cents per quarter.

The notes are callable upon the termination of Danaher’s acquisition of GE Life Sciences’ BioPharma division at the acquisition termination make-whole amount.

Net proceeds from the mandatory convertible preferred share offering are expected to be $1.45 billion, and net proceeds from the common stock offering are expected to be $1.31 billion.

Proceeds will be used to fund a portion of the cash consideration of the acquisition of GE Life Sciences’ BioPharma division.

Danaher is a Washington-based global science and technology company.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.